ความก้าวหน้าทางการวิจัยเกี่ยวกับการใช้สมุนไพรจีนในการควบคุมภาวะ ferroptosis เพื่อการรักษาโรคไตจากเบาหวาน
Article Sidebar
Main Article Content
บทคัดย่อ
โรคไตจากเบาหวาน (diabetic kidney disease) เป็นภาวะแทรกซ้อนรุนแรงของโรคเบาหวาน โดยแนวทางการรักษาที่มีอยู่ในปัจจุบันยังคงมีข้อจำกัดในการชะลอการดำเนินโรค ภาวะ ferroptosis ซึ่งเป็นรูปแบบหนึ่งของการตายของเซลล์ ที่พึ่งพาธาตุเหล็กและขับเคลื่อนโดยกระบวนการ lipid peroxidation มีความสัมพันธ์อย่างใกล้ชิดกับโรคไตจากเบาหวาน กลไกการเกิดโรคเกี่ยวข้องกับความไม่สมดุลของเมแทบอลิซึมของธาตุเหล็ก ความผิดปกติของระบบต้านอนุมูลอิสระ และการสะสมของ lipid peroxide accumulation ภาวะน้ำตาลสูงยิ่งทำให้ความเสียหายจากออกซิเดชันในไตรุนแรงขึ้น ส่งผลให้เกิดการแสดงออกผิดปกติของโปรตีนที่เกี่ยวข้องกับ ferroptosis เช่น การลดลงของ glutathione peroxidase 4 (GPX4) และส่งเสริมให้การทำงานของไตเสื่อมลง ศาสตร์การแพทย์แผนจีนมีข้อได้เปรียบจากคุณลักษณะขององค์ประกอบหลายชนิด และเป้าหมายการออกฤทธิ์หลายระดับ จึงอาจควบคุมภาวะ ferroptosis ผ่านกลไกต่างๆ ได้แก่ iron ion chelation การเสริมฤทธิ์ของเอนไซม์ต้านอนุมูลอิสระ และการยับยั้งกระบวนการ lipid peroxidation อันนำไปสู่การบรรเทาความเสียหายของไต ในอนาคตควรบูรณาการเทคโนโลยี multi-omics technologies เพื่อวิเคราะห์กลไกการออกฤทธิ์ให้ลึกซึ้งและเป็นระบบยิ่งขึ้น ควบคู่กับการยืนยันประสิทธิผลทางการรักษาผ่านการทดลองทางคลินิก ทั้งนี้ เพื่อพัฒนาแนวทางการรักษารูปแบบใหม่ที่ผสานศาสตร์การแพทย์แผนจีนเข้ากับการแพทย์ตะวันตกอย่างมีประสิทธิภาพ
Article Details
เอกสารอ้างอิง
Sun H, Saeedi P, Karuranga S, Pinkepank M, Ogurtsova K, Duncan BB, et al. IDF diabetes atlas: global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract. 2022;183:109119.
Diabetes Branch of Chinese Medical Association. Guidelines for the prevention and treatment of type 2 diabetes in China (2020 edition, Part 2). Chinese Journal of Practical Internal Medicine. 2021;41(9):757-84. (in Chinese)
Ayinde KS, Olaoba OT, Ibrahim B, Lei D, Lu Q, Yin XX, et al. AMPK allostery: a therapeutic target for the management/treatment of diabetic nephropathy. Life Sci. 2020;261:118455.
Jairoun AA, Ping CC, Ibrahim B. Pharmacotherapeutic considerations and treatment patterns of antihyperglycemic agents for diabetic nephropathy: a review of the literature. Eur Rev Med Pharmacol Sci. 2023;27(24):12058-69.
Tye SC, Denig P, Lambers Heerspink HJ. Precision medicine approaches for diabetic kidney disease: opportunities and challenges. Nephrol Dial Transplant. 2021;36(Suppl 2):3-9.
Wang H, Liu DW, Zheng B, Yang Y, Qiao YJ, Li SY, et al. Emerging role of ferroptosis in diabetic kidney disease: molecular mechanisms and therapeutic opportunities. Int J Biol Sci. 2023;19(9):2678-94.
Lu QY, Yang LJ, Xiao JJ, Liu Q, Ni LH, Hu JW, et al. Empagliflozin attenuates the renal tubular ferroptosis in diabetic kidney disease through AMPK/NRF2 pathway. Free Radic Biol Med. 2023;195:89-102.
Ji J, Tao PY, Wang Q, Cui MM, Cao MF, Xu YZ. Emodin attenuates diabetic kidney disease by inhibiting ferroptosis via upregulating Nrf2 expression. Aging (Albany NY). 2023;15(15):7673-88.
Dixon SJ, Lemberg KM, Lamprecht MR, Skouta R, Zaitsev EM, Gleason CE, et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell. 2012;149(5):1060-72.
Jia MT, Qin DH, Zhao CY, Chai L, Yu ZX, Wang WW, et al. Redox homeostasis maintained by GPX4 facilitates STING activation. Nat Immunol. 2020;21(7):727-35.
Lei PX, Bai T, Sun YL. Mechanisms of ferroptosis and relations with regulated cell death: a review. Front Physiol. 2019;10:139.
Chen X, Yu CH, Kang R, Tang DL. Iron metabolism in ferroptosis. Front Cell Dev Biol. 2020;8:590226.
Kagan VE, Mao GW, Qu F, Friedmann Angeli JP, Doll S, St Croix C, et al. Oxidized arachidonic and adrenic PEs navigate cells to ferroptosis. Nat Chem Biol. 2017;13(1):81-90.
Kim JW, Lee JY, Oh M, Lee EW. An integrated view of lipid metabolism in ferroptosis revisited via lipidomic analysis. Exp Mol Med. 2023;55(8):1620-31.
Ding KY, Liu CB, Li L, Yang M, Jiang N, Luo SL, et al. Acyl-CoA synthase ACSL4: an essential target in ferroptosis and fatty acid metabolism. Chin Med J (Engl). 2023;136(21):2521-37.
Tu H, Tang LJ, Luo XJ, Ai KL, Peng J. Insights into the novel function of system Xc- in regulated cell death. Eur Rev Med Pharmacol Sci. 2021;25(3):1650-62.
Tang DL, Chen X, Kang R, Kroemer G. Ferroptosis: molecular mechanisms and health implications. Cell Research. 2021;31:107-25.
Dodson M, Castro-Portuguez R, Zhang DD. NRF2 plays a critical role in mitigating lipid peroxidation and ferroptosis. Redox Biol. 2019;23:101107.
Wei TW, Qin Y, Lin XH, Wang XJ, Chen SY, Chen X, et al. Mapping the future: bibliometric insights into ferroptosis and diabetic nephropathy. Front Physiol. 2025;16:1516466.
Long ZY, Luo YF, Yu M, Wang XY, Zeng LT, Yang KL. Targeting ferroptosis: a new therapeutic opportunity for kidney diseases. Front Immunol. 2024;15:1435139.
Chen Y, Huang GD, Qin T, Zhang ZC, Wang HL, Xu YP, et al. Ferroptosis: a new view on the prevention and treatment of diabetic kidney disease with traditional Chinese medicine. Biomed Pharmacother. 2024;170:115952.
Li M, Zhao S, Liu Y, Wang Q, Chen YZ, Zhou YR. Pathological characteristics of ferroptosis in kidney tissues in type 2 diabetic patients with diabetic kidney disease. Diabetes Metab Syndr Obes. 2024;17:4105-13.
Shen R, Yu X, Shi CF, Fang Y, Dai CS, Zhou Y. ACSL4 predicts rapid kidney function decline in patients with diabetic kidney disease. Front Endocrinol (Lausanne). 2025;16:1499555.
Anandhan A, Dodson M, Shakya A, Chen JJ, Liu PF, Wei YY, et al. Nrf2 controls iron homeostasis and ferroptosis through HERC2 and VAMP8. Sci Adv. 2023;9(5):eade9585.
Jin T, Chen C. Umbelliferone delays the progression of diabetic nephropathy by inhibiting ferroptosis through activation of the Nrf-2/HO-1 pathway. Food Chem Toxicol. 2022;163:112892.
Wang YH, Chang DY, Zhao MH, Chen M. Glutathione peroxidase 4 is a predictor of diabetic kidney disease progression in type 2 diabetes mellitus. Oxid Med Cell Longev. 2022;2022:2948248.
Wang Y, Bi R, Quan F, Cao QH, Lin YT, Yue CX, et al. Ferroptosis involves in renal tubular cell death in diabetic nephropathy. Eur J Pharmacol. 2020;888:173574.
Wu ZY, Li D, Tian DY, Liu XJ, Wu ZM. Aspirin mediates protection from diabetic kidney disease by inducing ferroptosis inhibition. PLoS One. 2022;17(12):e0279010.
Wang X, Jiang L, Liu XQ, Huang YB, Zhu W, Zeng HX, et al. Identification of genes reveals the mechanism of cell ferroptosis in diabetic nephropathy. Front Physiol. 2022;13:890566.
Zhang QJ, Hu YC, Hu JE, Ding Y, Shen YQ, Xu H, et al. Sp1-mediated upregulation of Prdx6 expression prevents podocyte injury in diabetic nephropathy via mitigation of oxidative stress and ferroptosis. Life Sci. 2021;278:119529.
Wu KP, Fei LY, Wang XH, Lei Y, Yu L, Xu WQ, et al. ZIP14 is involved in iron deposition and triggers ferroptosis in diabetic nephropathy. Metallomics. 2022;14(7):mfac034.
Wu Y, Zhao Y, Yang HZ, Wang YJ, Chen Y. HMGB1 regulates ferroptosis through Nrf2 pathway in mesangial cells in response to high glucose. Biosci Rep. 2021;41(2):BSR20202924.
Kim S, Kang SW, Joo J, Han SH, Shin H, Nam BY, et al. Characterization of ferroptosis in kidney tubular cell death under diabetic conditions. Cell Death & Disease. 2021;12:160.
Huang JZ, Chen GY, Wang JL, Liu SB, Su J. Platycodin D regulates high glucose-induced ferroptosis of HK-2 cells through glutathione peroxidase 4 (GPX4). Bioengineered. 2022;13(3):6627-37.
Shan XM, Chen CW, Zou DW, Gao YB, Ba YY, He JX, et al. Suppression of ferroptosis through the SLC7A11/glutathione/glutathione peroxidase 4 axis contributes to the therapeutic action of the Tangshenning formula on diabetic renal tubular injury. Chin Med. 2024;19:151.
Xia ZR, Wei ZN, Li X, Liu YZ, Gu XC, Tong JH, et al. C/EBPα-mediated ACSL4-dependent ferroptosis exacerbates tubular injury in diabetic kidney disease. Cell Death Discov. 2024;10(1):448.
Zhang S, Zhang SX, Wang H, Chen Y. Vitexin ameliorated diabetic nephropathy via suppressing GPX4-mediated ferroptosis. Eur J Pharmacol. 2023;951:175787.
Wang Y, Quan F, Cao QH, Lin YT, Yue CX, Bi R, et al. Quercetin alleviates acute kidney injury by inhibiting ferroptosis. J Adv Res. 2020;28:231-43.
Tan HT, Chen JX, Li YC, Li YS, Zhong YC, Li GZ, et al. Glabridin, a bioactive component of licorice, ameliorates diabetic nephropathy by regulating ferroptosis and the VEGF/Akt/ERK pathways. Mol Med. 2022;28(1):58.
Ge CX, Xu MX, Qin YT, Gu TT, Lou DS, Li Q, et al. Fisetin supplementation prevents high fat diet-induced diabetic nephropathy by repressing insulin resistance and RIP3-regulated inflammation. Food Funct. 2019;10(5):2970-85.
Huang D, Shen PC, Wang C, Gao JD, Ye CY, Wu F. Calycosin plays a protective role in diabetic kidney disease through the regulation of ferroptosis. Pharm Biol. 2022;60(1):990-6.
Xiong D, Hu W, Han XF, Cai YH. Rhein inhibited ferroptosis and EMT to attenuate diabetic nephropathy by regulating the Rac1/NOX1/β-Catenin axis. Front Biosci (Landmark Ed). 2023;28(5):100.
Wang MZ, Cai YF, Fang QJ, Liu YL, Wang J, Chen JX, et al. Inhibition of ferroptosis of renal tubular cells with total flavones of Abelmoschus manihot alleviates diabetic tubulopathy. Anat Rec (Hoboken). 2023;306(12):3199-213.
Chen J, Ou ZJ, Gao TT, Yang YW, Shu AM, Xu HQ, et al. Ginkgolide B alleviates oxidative stress and ferroptosis by inhibiting GPX4 ubiquitination to improve diabetic nephropathy. Biomed Pharmacother. 2022;156:113953.
Ding Y, Wang L. Mechanism exploration of sennoside A in treating DN based on Nrf2/HMOX-1 ferroptosis signaling pathway. Information on Traditional Chinese Medicine. 2021;38(7):36-9. (in Chinese)
Lu JH, Liu AJ. Crocetin inhibits high glucose-induced ferroptosis in human glomerular mesangial cells through regulating Nrf2/HO-1 pathway. Traditional Chinese Drug Research and Clinical Pharmacology. 2023;34(1):8-15. (in Chinese)
Ran Z, Wang YJ, Wang Z, Zhao TQ, Hou SZ. Glycyrrhizic acid inhibits high glucose induced extracellular matrix synthesis in mice glomerular mesangial cells by regulating TGF-β1/Smads signaling pathway. Journal of Ningxia Medical University. 2021;43(4):371-6. (in Chinese)
Peng ZN. To explore the mechanism of Huoxue Digui decoction in treating diabetic kidney disease based on the regulation of ferroptosis in podocyte by arachidonic acid metabolic pathway [dissertation]. Zhengzhou: Henan University of Chinese Medicine; 2022. (in Chinese)
Zheng LL, Guo DZ. Effect of Buyang Huanwutang on ferroptosis in diabetic kidney disease mice. Chinese Journal of Experimental Traditional Medical Formulae. 2023;29(17):34-41. (in Chinese)
Lv SQ, Li HJ, Zhang TY, Su XH, Sun WJ, Wang QH, et al. San-Huang-Yi-Shen capsule ameliorates diabetic nephropathy in mice through inhibiting ferroptosis. Biomed Pharmacother. 2023;165:115086.
Li YC. Mechanism study of Chinese herbal compound Yitangkang in preventing and treating diabetic kidney injury by regulating SLC7A11/GPX4-mediated ferroptosis [dissertation]. Shenyang: Liaoning University of Traditional Chinese Medicine; 2022. (in Chinese)
Wang ZB, Zou XL, Zou YX, Wang LH, Wu YT. Shenqi Dihuang decoction inhibits high-glucose induced ferroptosis of renal tubular epithelial cells via Nrf2/HO-1/GPX4 pathway. China Journal of Chinese Materia Medica. 2023;48(19):5337-44. (in Chinese)
Zhang Y, Gao ZH, Liu JQ, Xu ZH. Protective effects of baicalin and quercetin on an iron-overloaded mouse: comparison of liver, kidney and heart tissues. Nat Prod Res. 2011;25(12):1150-60.
Chen XY, Meng XY, He YT, Cai WW, Hou B, Qiu LY, et al. Research progress of active components of Chinese materia medica intervening ferroptosis for the treatment of diabetic nephropathy. Chinese Journal of Information on Traditional Chinese Medicine. 2025;32(3):192-7. (in Chinese)
